Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
If you are having surgery for a NET tumor, consider donating some of your tumor tissue to help research. The Neuroendocrine Tumor Research Foundation is
The Neuroendocrine Tumor Research Foundation (NETRF) has invested more than $1.5 million in advancing a precision form of radiation therapy for NETs called Peptide Receptor
Can an epigenetic enzyme under the right conditions contribute to the growth of cancer cells? If so, what happens if the enzyme is removed? Can
Request for Applications Issued The Neuroendocrine Tumor Research Foundation (NETRF) has announced its latest Request for Applications (RFA) and invites innovative research applications in neuroendocrine
NETRF announces the appointment of Susan Payson as Chief Development Officer. In this new position, Susan will work to expand NETRF’s base of support to
The first step in curing a disease is understanding it. Unfortunately, there is a lot we still don’t know about small-intestinal NETs (SI-NETs). That’s why
NETRF awarded six new research grants totaling $1.85 million to leading academic institutions around the world. The goal of the funding is to improve current treatments for neuroendocrine tumors (NETs), an uncommon and poorly understood cancer, which occurs in the body’s hormone-producing cells.
New treatment for GI and pancreatic NETs The U.S. Food and Drug Administration (FDA) has approved Peptide Receptor Radionuclide Therapy (PRRT) with a new radiopharmaceutical for
World renown laboratory in the Netherlands to grown min-organs in Petri dishes to speed up NET drug testing.
Even those who did not know her were inspired by the stories of Meg’s positive, generous spirit, her sense of humor, and ability to squeeze so much life into her 31+years. Nurse Meg took care of us all and is forever in our hearts—forever running alongside encouraging us to dream bigger and live stronger—and find and inspire laughter and joy each day.